Claims for Patent: 4,597,961

Summary for Patent: 4,597,961

Title:	Transcutaneous application of nicotine
Abstract:	Percutaneous administration of nicotine in a dose approximating the dose delivered by a variety of nicotine-containing products, such as cigarettes, cigars, snuff and chewing tobacco, is carried out using an occlusive pad. The nicotine is delivered so as to mimic the pharmacological effects of nicotine provided by the conventional use of tobacco, and a therapeutic function is achieved by reducing or eliminating the need for the tobacco product. A suitable transdermal application pad comprises a reservoir for liquid nicotine base to be affixed to the skin in a variety of places. Due to the high lipid solubility and resultant high skin permeability of nicotine, vehicles or solvents are not generally needed to enhance dermal absorption.
Inventor(s):	Etscorn; Frank T. (Socorro, NM)
Assignee:
Application Number:	06/694,047
Patent Claims:	1. A method of administering nicotine for the purpose of satisfying a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with products of combustion of tobacco, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate sufficient to satisfy said nicotine habit, said occlusive pad comprising a nicotine-impermeable backing and nicotine-permeable, porous, inert membrane, said nicotine impermeable backing and said nicotine-permeable membrane defining a cavity therebetween, said cavity containing liquid nicotine therein. 2. A method according to claim 1 wherein said nicotine is in the form of nicotine base without a solvent, vehicle or carrier. 3. A method according to claim 1 wherein said nicotine is in the form of nicotine base diluted with a pharmaceutically acceptable carrier, solvent or vehicle which reduces penetration of the nicotine base through the skin. 4. A method according to claim 1 wherein said nicotine is administered by application to the skin behind the ear. 5. A method according to claim 1 wherein said pad comprises 1-4 microliters of nicotine base. 6. A method according to claim 1 wherein said nicotine is transdermally administered at a dosage rate of 15-25 nanograms per liter of blood. 7. A method of administering nicotine for the purpose of satisfying a nicotine habit in accordance with claim 1, wherein said nicotine is transdermally administered to a patient physically addicted to nicotine. 8. A method of assisting a person to quit smoking, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at at a dosage rate approximately the same as provided when absorbing nicotine by smoking, said occlusive pad comprising a nicotine-impermeable backing and nicotine-permeable, porous, inert membrane, said nicotine-impermeable backing and said nicotine-permeable membrane defining a cavity therebetween, said cavity containing liquid nicotine therein. 9. A method according to claim 8 comprising carrying out a series of said transdermal administrations and interspercing said transdermal administrations with cigarettes to slowly extinguish the reinforcing properties of non-pharmacological factors. 10. A method according to claim 8 wherein said pad comprises 1-4 microliters of nicotine base. 11. A method according to claim 10 wherein said nicotine is in the form of nicotine base without a solvent, vehicle or carrier. 12. A method according to claim 10 wherein said nicotine is in the form of nicotine base diluted with a pharmaceutically acceptable carrier, solvent or vehicle which reduces penetration of the nicotine base through the skin. 13. A method according to claim 10 wherein said nicotine is administered by application to the skin behind the ear. 14. A method according to claim 8 wherein said nicotine is transdermally administered at a dosage level of 15-25 nanograms per liter of blood. 15. A method of administering nicotine for the purpose of satisfying a nicotine habit in accordance with claim 8, wherein said nicotine is transdermally administered to a patient physically addicted to nicotine. 16. A method of administering nicotine for the purpose of satisfying a nicotine habit while minimizing or eliminating side effects caused by absorbing nicotine through the lungs along with products of combustion of tobacco, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate sufficient to satisfy said nicotine habit, said occlusive pad comprising a nicotine impermeable backing defining a cavity therein, and an absorbant material having absorbed nicotine therein, within said cavity. 17. A method according to claim 16 wherein said pad comprises 1-4 microliters of nicotine base. 18. A method of assisting a person to quit smoking, comprising transdermally administering nicotine via an occlusive pad adhered to the skin at a dosage rate approximately the same as provided when absorbing nicotine by smoking, said occlusive pad comprising a nicotine impermeable backing defining a cavity therein, and an absorbant material having absorbed nicotine therein within said cavity. 19. A method according to claim 18 wherein said pad comprises 1-4 microliters of nicotine base.